Public support for medications like Ozempic clashes with Medicare policy gaps Despite strong public backing for Medicare to cover GLP-1s for weight loss (61%), current policy only covers them for certain conditions
This is associated with low volume high flow POTS seen in MCAS and EDS with histamine intolerance
At baseline, patients had type 2 diabetes mellitus for an average of 8.8 years and had a mean HbA1c of 8.2%
BPC-157 supports this interconnected system by: Strengthening tight junctions between intestinal epithelial cells, reducing intestinal permeability (leaky gut) Modulating the enteric nervous system to normalize motility and reduce visceral hypersensitivity Regulating mucosal immune responses to prevent inappropriate inflammation against dietary and microbial antigens Conditions Treated with Oral BPC-157 Beyond Symptom Relief: Addressing Root Causes Unlike proton pump inhibitors (PPIs) that suppress stomach acid or corticosteroids that broadly dampen immunity, BPC-157 works by restoring the underlying structural and functional integrity of the gastrointestinal tract
However, these treatments arent suitable for significant weight loss or as a substitute for surgery in extreme cases
For Aplnr-CreERT2 -controlled Flt4 loss-of-function experiments, Flt4 i Aplnr KO ( Flt4 lox/lox Aplnr-CreERT2 tg/+ ) embryos were compared with control littermates ( Flt4 lox/lox Aplnr-CreERT2 +/+ )
